Insurance coverage for antiobesity medications continues to evolve rapidly, leaving many primary care physicians (PCPs) navigating an increasingly complex landscape of formularies, prior authorization requirements, and shifting payer policies.

While demand for GLP-1 receptor agonists and dual incretin therapies continues to surge, access remains uneven across Medicare, Medicaid, and commercial insurance plans.

For clinicians and patients alike, the result is a confusing patchwork of eligibility rules, documentation requirements, and cost barriers.

“We have those conversations almost daily with patients,” said Joseph Barrera, MD, an endocrinologist at Providence Mission Heritage Medical Group, Rancho Mission Viejo, California. “It seems like there have been lots of changes since the start of the year, and in many cases, it’s actually becoming harder to get these medications covered, not easier.”

A Complex and Changing Coverage Landscape 

Historically, federal law has limited coverage of antiobesity medications under Medicare, which has influenced policies across the broader insurance market.

“Patients have been able to obtain coverage for GLP-1 medications for secondary diagnoses such as diabetes or cardiovascular risk, but historically, they have not been covered directly for weight management,” said Alexander Nathanson, MD, owner of Navigate Weight & Metabolic in New York City.

Although policymakers have discussed expanding coverage, Nathanson said, changes are likely to occur gradually.

“We will likely see expanded Medicare coverage later in 2026, but it won’t be universal immediately,” he said. “It will likely begin with the highest-acuity patients and expand over time.”

At the same time, coverage policies continue to differ widely across insurers and government programs.

“Coverage for GLP-1 medications remains highly dependent on both the indication and the type of insurance a patient carries,” said Whitney Stidom, vice president of consumer enablement at eHealth.

“While most Medicare Advantage and ACA [Affordable Care Act] plans cover at least one GLP-1 for diabetes management, coverage for obesity alone is still uncommon,” she said. “Employer-sponsored plans vary significantly, and high-deductible plans may leave patients facing substantial upfront costs even when a drug is technically covered.”

According to 2024 eHealth data, about 98% of Medicare Advantage plans cover at least one GLP-1 medication for diabetes treatment, but fewer than 1% offer coverage specifically for obesity. Among ACA marketplace plans, more than 90% cover GLP-1 medications for diabetes, whereas only about 3% cover them for weight loss alone.

Employer-sponsored coverage also varies widely: roughly 55% of employers cover GLP-1 therapies for diabetes, but only 36% provide coverage when the indication is obesity.

Expanded Indications but Persistent Barriers 

Some coverage pathways have expanded as GLP-1 medications gain additional indications.

“Coverage for antiobesity medications for patients with specific associated conditions, such as obstructive sleep apnea or metabolic dysfunction-associated fatty liver disease, has expanded,” said Eleanor Yusupov, DO, assistant professor at the New York Institute of Technology College of Osteopathic Medicine, Long Island, New York.

Unfortunately, Yusupov said that even if patients can access the drugs, other obstacles may stand in the way.

“Patients continue to experience high costs and insurance barriers in 2026,” Yusupov said. “Additional cost reductions have been announced and are expected to be effective in the coming months.”

Coverage differences are particularly evident in public insurance programs.

“Medicaid coverage varies between states and can even vary depending on the specific Medicaid program within the state, as we see in New York,” Yusupov said. “Out-of-pocket costs for Medicare patients continue to leave these treatments out of reach for many people.”

Some of the most meaningful price shifts this year have come directly from pharmaceutical manufacturers.

“As a result of political pressure and direct competition between Eli Lilly and Novo Nordisk, we have seen prices for Zepbound and Wegovy come down if purchased directly from these companies, bypassing retail pharmacies,” Yusupov said.

Clinicians Navigating Administrative Hurdles 

In the clinic, even when coverage is ultimately available for a patient, it’s a complicated effort to obtain approval, requiring not only the physician’s attention but that of the support team to surmount significant administrative challenges.

“We have a whole team that goes through the chart if we put in a prescription,” Barrera said. “They’ll look for diagnoses that might allow it to be covered.”

In addition to diabetes and obesity with specific BMI thresholds, clinicians may document additional conditions that qualify patients for certain medications.

“Sometimes we’re doing sleep studies to look for a sleep apnea diagnosis or ordering imaging studies to evaluate for MASH [metabolic dysfunction-associated steatohepatitis],” Barrera said. “We may end up doing additional testing just to see if there’s an indication that allows the medication to be covered.”

Yusupov said, careful documentation can help reduce preventable denials.

“Having documentation of associated conditions, such as type 2 diabetes, sleep apnea, liver or cardiac disease, can help with prior authorization requirements,” she said.

Patients often request specific medications by name, which can also create challenges.

“Patients often ask for drugs like Mounjaro or Ozempic,” Yusupov said. “PCPs need to ensure that the appropriate supporting diagnosis, such as type 2 diabetes, is documented to avoid preventable denials.”

Reauthorization requirements also contribute to treatment interruptions.

“Close follow-up of patients on weight-loss treatment with documentation of their progress and lifestyle modifications is very important, as this information is often required for reauthorization,” Yusupov said.

Several of these specialists noted that this type of monitoring has contributed to the substantial growth of the administrative workload in their system.

“We have a whole prior authorization team for a large healthcare organization,” Barrera said. “I would estimate that fully 20%-25% of their time is spent on GLP-1 medications.”

Consequences of Treatment Interruptions 

The goal, of course, is to work with these evolving insurance requirements to ensure that patients taking these medications remain covered and can continue to take their medications affordably. That’s why these doctors and their teams scour patients’ charts looking for applicable comorbidities if necessary: because for patients who lose coverage, the clinical consequences can be significant.

“With interruptions in treatment, patients risk weight regain and reversing the health benefits of weight loss,” Yusupov said. “We also often see worsening of hemoglobin A1c, lipids, joint pain, or increases in blood pressure when weight-loss medications are stopped.”

Yusupov said, the psychological effects can also be substantial.

“Patients often feel defeated as a result,” Yusupov said.

Barrera said, many patients must revert to older treatment strategies when coverage is lost.

“We can always control blood sugar,” he said. “But sometimes that means going back to medications that don’t help with weight — or even adding insulin.”

Barrera said, that getting a handle on how to proceed is highly important in this moment, as physicians are switching over from viewing GLP-1s as a “quick fix” to understanding them as more of a long-term therapy.

“People have to be prepared for long-term use of the medication. I think we’re learning more and more that if people stop, the weight gain returns,” Barrera said. “I had those conversations today with a couple of patients, telling them, ‘Well, when do we get off the medicine?’ I said, ‘I don’t know if you ever will.’ I mean, it’s an admirable goal, but you’ve been taking blood pressure medicine for years and probably have no intention of getting off of those. Why? Why think of these medications any differently?”

Strategies for PCPs

Even well staffed practices struggle with the administrative burden associated with these therapies, Yusupov said.

“Primary care physicians, endocrinologists, and weight management specialists often report feeling overwhelmed by the demands of medication access issues,” she said.

Setting realistic expectations early can help.

“Advising patients to check their insurance coverage and educating them about the specific indications for each medication can be helpful,” Yusupov said.

Careful documentation is also critical.

“Documenting patient progress, previous treatments, lifestyle interventions, and associated conditions is the most effective strategy for navigating insurance requirements,” she said.

She also recommended ensuring patients return for follow-up visits before running out of medication, since reauthorization requests can take time.

Looking Ahead

Although access remains uneven, insurers and policymakers are closely monitoring the growing body of outcomes data associated with these therapies.

“As a broker, I can assure you the companies I work with have their members’ health and wellness at the forefront,” said Susannah Lee of The Lee Group, an insurance brokerage based in South Carolina.

“If these prescriptions have long-term impacts on reducing obesity, I’d look for an expansion of offerings,” she said.

Yusupov said, competition between drug manufacturers and increasing clinical evidence may eventually improve access.

“Coverage by Medicare and Medicaid is expected to expand due to competition, new therapies becoming available, and political pressure,” she said. “Hopefully, commercial insurance coverage will follow as well.”

For now, however, clinicians must prepare patients for potential delays and coverage uncertainty.

“Prior authorization is required by virtually every insurance company,” Yusupov said. “Patients should understand that approval can take time.”

No reported disclosures.